JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core MSCI EAFE ETF
IEFA
|
+$2.04B |
| 2 |
iShares MSCI EAFE ETF
EFA
|
+$1.31B |
| 3 |
Apple
AAPL
|
+$746M |
| 4 |
Trane Technologies
TT
|
+$676M |
| 5 |
AABA
Altaba Inc
AABA
|
+$658M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P Mid-Cap ETF
IJH
|
+$2.16B |
| 2 |
Honeywell
HON
|
+$701M |
| 3 |
iShares Russell Mid-Cap ETF
IWR
|
+$667M |
| 4 |
Vanguard Morningstar Mid-Cap ETF
VO
|
+$656M |
| 5 |
General Motors
GM
|
+$586M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 22.9% |
| 2 | Financials | 14.86% |
| 3 | Technology | 11.73% |
| 4 | Healthcare | 9.66% |
| 5 | Consumer Discretionary | 8.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2026
Dime Commercial Bancshares
DCOM
$1.74B
| $8.05M | ﹤0.01% |
241,669
-17,879
| -7% | -$613K |
2013 Q2
16 quarters
|
|
|
RDUS
2027
DELISTED
Radius Recycling
RDUS
| $8.04M | ﹤0.01% |
319,097
-71,117
| -18% | -$1.41M |
2013 Q2
16 quarters
|
|
2028
Cedar Fair
FUN
$1.24B
| $8.03M | ﹤0.01% |
111,370
+41,034
| +58% | +$2.89M |
2013 Q2
16 quarters
|
|
2029
Iovance Biotherapeutics
IOVA
$6.41B
| $8.01M | ﹤0.01% |
+1,089,173
| New | +$6.92M |
2017 Q2
0 quarters
|
|
2030
iShares S&P Small-Cap 600 Value ETF
IJS
$7.77B
| $7.99M | ﹤0.01% |
114,344
+6,252
| +6% | +$432K |
2013 Q2
16 quarters
|
|
|
ILG
2031
DELISTED
ILG, Inc Common Stock
ILG
| $7.97M | ﹤0.01% |
289,979
-389,768
| -57% | -$9.87M |
2015 Q4
6 quarters
|
|
2032
iShares MSCI Australia ETF
EWA
$1.21B
| $7.92M | ﹤0.01% |
365,199
+25,104
| +7% | +$551K |
2013 Q2
16 quarters
|
|
|
WBA
2033
PUT
DELISTED
Walgreens Boots Alliance
WBA
| $7.92M | ﹤0.01% |
101,100
-44,700
| -31% | -$3.68M |
2014 Q3
11 quarters
|
|
2034
AMN Healthcare
AMN
$1.43B
| $7.91M | ﹤0.01% |
202,448
-22,468
| -10% | -$862K |
2013 Q2
16 quarters
|
|
|
NSL
2035
DELISTED
NUVEEN SENIOR INCM FD
NSL
| $7.9M | ﹤0.01% |
1,158,717
| – | – |
2013 Q2
16 quarters
|
|
2036
IDT Corp
IDT
$1.99B
| $7.9M | ﹤0.01% |
649,871
+35,612
| +6% | +$462K |
2013 Q2
16 quarters
|
|
2037
Axsome Therapeutics
AXSM
$9.28B
| $7.9M | ﹤0.01% |
1,435,888
-160,011
| -10% | -$670K |
2015 Q4
6 quarters
|
|
2038
SITE Centers
SITC
$170M
| $7.9M | ﹤0.01% |
675,835
+164,059
| +32% | +$2.14M |
2013 Q2
16 quarters
|
|
|
HES
2039
PUT
DELISTED
Hess
HES
| $7.9M | ﹤0.01% |
180,000
| – | – |
2016 Q2
4 quarters
|
|
2040
BHP
BHP
$221B
| $7.88M | ﹤0.01% |
248,372
-86,203
| -26% | -$2.73M |
2013 Q2
16 quarters
|
|
|
VSM
2041
DELISTED
Versum Materials, Inc.
VSM
| $7.86M | ﹤0.01% |
308,045
+50,091
| +19% | +$1.56M |
2016 Q4
2 quarters
|
|
2042
CALL
Yum! Brands
YUM
$37.4B
| $7.85M | ﹤0.01% |
106,400
+56,400
| +113% | +$3.92M |
2016 Q2
4 quarters
|
|
|
MSCC
2043
DELISTED
Microsemi Corp
MSCC
| $7.84M | ﹤0.01% |
167,576
+71,069
| +74% | +$3.48M |
2013 Q2
16 quarters
|
|
2044
CALL
Gildan
GIL
$7.53B
| $7.84M | ﹤0.01% |
+255,000
| New | +$7.33M |
2017 Q2
0 quarters
|
|
2045
Interface
TILE
$2.01B
| $7.82M | ﹤0.01% |
398,101
-120,092
| -23% | -$2.36M |
2015 Q2
8 quarters
|
|
|
LOGM
2046
DELISTED
LogMein, Inc.
LOGM
| $7.82M | ﹤0.01% |
74,843
-127,355
| -63% | -$13.9M |
2015 Q3
7 quarters
|
|
|
ESPR
2047
DELISTED
Esperion Therapeutics
ESPR
| $7.81M | ﹤0.01% |
168,800
-15,108
| -8% | -$556K |
2015 Q3
7 quarters
|
|
2048
CALL
Zoetis
ZTS
$29.5B
| $7.8M | ﹤0.01% |
125,000
| – | – |
2017 Q1
1 quarter
|
|
2049
First Financial Bankshares
FFIN
$4.59B
| $7.79M | ﹤0.01% |
352,624
-96,986
| -22% | -$1.94M |
2013 Q2
16 quarters
|
|
2050
iShares Latin America 40 ETF
ILF
$4.22B
| $7.78M | ﹤0.01% |
256,884
+142,092
| +124% | +$4.4M |
2013 Q2
16 quarters
|
|
Similar funds
JP Morgan Chase's Q2 2017 Portfolio in Review
As of Q2 2017, JP Morgan Chase held 5,542 positions worth $438B, down 0.01% from $438B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
JP Morgan Chase's Q2 2017 filing shows 462 new, 1,879 increased, 2,145 reduced and 563 closed positions. Its largest new stake was Altaba Inc: 12,081,650 shares worth $658M. The largest sale was iShares Core S&P Mid-Cap ETF, an estimated $2.16B.
By sector, the portfolio is most concentrated in Miscellaneous at 23% of assets, down from 24% a quarter earlier, followed by Financials and Technology.
- JP Morgan Chase's largest Q2 2017 buy was Altaba Inc: 12,081,650 shares worth $658M.
- JP Morgan Chase added most to iShares Core MSCI EAFE ETF in Q2 2017, an estimated $2.04B increase.
- JP Morgan Chase's biggest Q2 2017 reduction was iShares Core S&P Mid-Cap ETF, cutting an estimated $2.16B.
- JP Morgan Chase fully exited Energy Transfer Partners L.p. in Q2 2017, selling an estimated $439M.
- JP Morgan Chase's ten largest holdings make up 18% of its $438B portfolio in Q2 2017.
- JP Morgan Chase opened 462 new positions and closed 563 in Q2 2017.
- JP Morgan Chase's portfolio value fell 0.01% quarter-over-quarter to $438B.
Based on JP Morgan Chase's 13F filing for Q2 2017, filed 9 Aug 2017.